news: Avastin still topical conversation in oncology research

The conversation about antiangiogenic treatment for breast cancer continues. Published in the 12/1/11 issue of the Journal of Clinical Oncology, Drs. Schneider and Sledge elucidate the topic in the wake of the US Food and Drug Administration’s (FDA) revocation of Avastin® (bevacizumab) as an approved treatment for metastatic breast cancer. You may recall that Dr. Sledge is the Immediate Past President of the American Society of Clinical Oncology (ASCO); both Sledge and Schneider are oncologists at the Indiana University Melvin and Bren Simon Cancer Center.

Bryan P. Schneider and George W. Sledge Jr. Anti–Vascular Endothelial Growth Factor Therapy for Breast Cancer: Can We Pick the Winners? Journal of Clinical Oncology 12-1-11

5 6 7 8
© 2004–2011 Donna Peach. All rights reserved.

Advertisements

One response to “news: Avastin still topical conversation in oncology research

  1. Questione è una risposta diversa

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s